Participated · Series A · Jun 2022

Peptone is a London, UK–based molecular computational physics company focused on protein drug discovery. It combines advanced biophysics, atomic-level experimental approaches, high-performance supercomputing, and machine learning to address biopharmaceutical R&D challenges. The company concentrates on intrinsically disordered proteins (IDPs), a class of proteins without fixed structure that play significant roles in health and disease and have been historically difficult to drug. Peptone's proprietary approaches aim to explore IDPs and enable discovery of novel therapeutics against previously undruggable targets. In June 2022 Peptone closed a $40M Series A financing. The round will be used to develop an advanced facility dedicated to solving complex and problematic IDP structures at scale and to pioneer a new class of potential therapeutic targets and drugs. Peptone is a computational physics company that developed one of the world’s first protein engineering operating systems, PeOS. PeOS uses state-of-the-art computational molecular physics orchestrated by AI and reinforcement learning to run massively parallel molecular simulations. The platform sifts through millions of protein feature anomalies to assess the likelihood of failure and suggests routes to resolution, automating the search for non-obvious protein variants with therapeutic potential and manufacturability. The team, led by physicist and founder Dr. Kamil Tamiola and including co-founders Kamil and Matt, comprises physicists, structural biologists, computer engineers and mathematicians who spent years building the foundations of PeOS. Peptone collaborated exclusively with NVIDIA to develop its supercomputing and AI solutions. The company is in talks with pharmaceutical players about partnerships and has raised funding to further develop its technology and reduce early-stage drug development failure risk.

Participated · Series C · Sep 2021

Flywheel offers an enterprise imaging platform that aggregates, curates, and analyzes medical imaging and video data at scale, helping customers streamline research workflows and prepare AI-ready datasets. During 2025 the company broadened its product suite with a video viewing and annotation tool and launched Flywheel Validated, which supports 21 CFR Part 11–compliant imaging workflows for clinical trials. Its customer roster now includes 10 of the top 20 global pharmaceutical companies and 10 of the top 20 academic medical centers. Commercial traction was strong, with 43 % year-over-year growth in new business, a 40 % increase in committed revenue, and annual recurring revenue from pharma and device customers up 106 %. Net revenue retention exceeded 110 %, underscoring sticky usage and expansion within existing accounts. Backers of the company include Novalis LifeSciences, 8VC, NVIDIA, Microsoft, Novartis, and Intuitive Surgical. The new capital will be used to accelerate product innovation and further penetrate the clinical trial and AI model development markets.

Participated · Series B · Dec 2020

H1 is a nine-year-old healthcare data platform that compiles and sells detailed information about physicians to pharma companies, hospital systems, and health insurers. The company emphasizes that its core asset is proprietary provider data, which it views as difficult for AI models to replicate and potentially valuable to AI model makers. H1 turned cash flow and EBITDA profitable last year and is forecasting more than 40% growth this year. The startup has grown organically and through acquisitions of smaller competitors and complementary businesses. H1 raised $100 million led by Altimeter Capital in November 2021 at a $750 million valuation. The recent investment by CVS Health Ventures establishes a strategic partnership with a major healthcare company.